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Introduction 
Hepatic fibrosis (HF) is the accumulation of  extracellular matrix, 
or scar, in response to acute or chronic liver injury. Fibrogenesis 
represents a wound healing response to injury, and ultimately leads 
to cirrhosis. Cirrhosis is the end-stage consequence of  fibrosis 
of  the hepatic parenchyma, resulting in nodule formation that 
may lead to altered hepatic function and blood flow[1]. Alcohol 
abuse, chronic viral hepatitis (HBV and HCV), obesity, autoim-
mune hepatitis, parasitic diseases (i.e. schistosomiasis), metabolic 
disorders (hemochromatosis and wilson's disease), biliary disease, 
persistent exposure to toxins and chemicals, and drug-induced 
chronic liver diseases are the most common causes of  hepatic 
fibrosis [2]. Hepatic stellate cells are the major source of  fibrillar 
collagens and other ECM proteins that characterize liver fibrosis 
[3]. As the liver becomes fibrotic, the total content of  collagens 
and non-collagenous components increases three-to fivefold, ac-
companied by a shift in the type of  ECM in the subendothelial 
space from the normal low-denisty basement membrane-like ma-
trix to interstitial-type matrix [4]. This 'capillarization' leads to the 
loss of  hepatocyte microvilli and the disappearance of  endothe-
lial fenestration. MMPs are the main enzymes responsible for 
ECM degradation and TIMPs have the ability to inhibit MMPs 
[5]. Mesenchymal stem cells (MSCs) have been isolated from sev-
eral sources, BM, cord blood, amniotic fluid, placenta and adipose 
tissue, and therefore, become a prime candidate for cell therapy. 
Several studies have demonstrated that MSCs isolated and ex-
panded in vitro can be induced to differentiate into hepatocyte-like 
cells [6]. HSCs obtained from cord blood have been shown to be 
a suitable alternative to adult bone marrow or peripheral blood 
in transplants for the treatment of  leukemia, lymphoma, aplas-
tic anemia, and inherited disorders of  immunity and metabolism 
[7]. Traditionally HSCs generate all mature blood cell types of  
the hematolymphatic system. More recently, HSCs have shown 
to display remarkable plasticity and can apparently differentiate 
into several non-hemolymphatic tissue lineages [8]. Therefore, 
UBCs may become a hopeful candidate for a hepatocyte progeni-
tor source like BMCs. Therefore, the aim of  the present work was 
to investigate the therapeutical role of  stem cell transplantation in 
the experimental rat liver fibrosis and compare the proliferative 
potency of  them.
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Materials and Methods
Preparation of  BM-derived MSCs
 
Bone marrow was harvested by flushing the tibiae and femurs of  
6 weeks old male white albino rats, weighing between 140 and 
160g, with Dulbecco’s modified Eagle’s medium (DMEM, GIB-
CO/BRL) supplemented with 10% fetal bovine serum (GIBCO/
BRL). Nucleated cells were isolated with a density gradient [Fi-
coll/Histopaque (Pharmacia)] and resuspended in complete 
culture medium supplemented with 1% penicillin-streptomycin 
(GIBCO/BRL). Cells were incubated at 37°C in 5% humidified 
CO2 for 12- 14 days. Media was changed every 3-4 days. When 
large colonies developed (80-90% confluence), cultures were 
washed twice with phosphate buffer saline (PBS) and cells were 
trypsinized with 0.25% trypsin in 1mM Ethylene Diamine Tetra 
Acetate (EDTA) (GIBCO/BRL) for 5 minutes at 37°C. After 
centrifugation, cell pellets were resuspended with serum-supple-
mented medium and incubated in 50 cm2 culture flask (Falcon). 
The resulting cultures were referred to as first-passage cultures 
[9]. MSCs in culture were characterized by their adhesiveness and 
fusiform shape [10]. We also detected CD29 gene expression by 
RT-PCR as a marker of  MSCs [11].
 
Isolation of  CD34+ stem cells
 
Human Umbilical Cord Blood (UCB) was used for separation of  
mononuclear cells (MNCs) after obtaining an informed consent 
and research ethics committee approval. Anticoagulated cord 
blood was diluted 1:4 with PBS containing 2 mM EDTA (Gibco-
Invitrogen, Grand Island, NY) and 35 ml of  the diluted sample 
was carefully layered on 15 ml Ficoll-Paque (Gibco-Invitrogen, 
Grand Island, NY), then they were centrifuged for 35 min. at 
400xg rpm. CD34+ HSC were isolated from UCB using MACS 
(magnetic cell sorting) kits (MiniMACS; Miltenyi Biotec, Bergisch 
Gladbach, Germany) according to Gordon et al. 2006 [12].
 
Labeling of  stem cells with PKH26
 
Two types of  stem cells were labeled with PKH26, which is a 
red fluorochrome. It has excitation (551nm) and emission (567 
nm) characteristics compatible with rhodamine or phycoeryth-
rin detection systems. The linkers are physiologically stable and 
show little to no toxic side-effects on cell systems. Labeled cells 
retain both biological and proliferating activity, and are ideal for 
in vitro cell labeling, in vitro proliferation studies and long, in vivo 
cell tracking. In the current work, MSCs were labeled with PKH26 
from Sigma Company (Saint Louis, Missouri USA). Cells were 
centrifuged and washed twice in serum free medium. Cells were 
pelleted and suspended in dye solution. Cells were injected intra-
peritoneally in rats. After one month, liver tissue was examined 
with a fluorescence microscope to detect and trace the cells.
 
CCl4-induced liver fibrosis model and MSC administration
 
Thirty male white Albino rats were 6 weeks old, weighing between 
150 and 200 g constituted the materials of  this work. The animals 
were housed in well ventilated hygienic experimental animal house 
under constant environmental and nutritional conditions. Liver 
fibrosis was induced by CCl4 injected by subcutaneous route at a 
dose of  0.2 mL/100 g body weight of  40 mL/L CCl4 (99 % pu-
rity, Sigma, St Louis, USA) dissolved in equal volume of  castor oil 
(Sigma, St. Louis, USA). The injection was given twice a week for 
6 weeks according to Zhao et al., 2005 [13]. The same volume of  
castor oil alone was used as a control. The delay in administration 
of  stem cells until 6 weeks of  injection of  CCl4 was suggested 
by histopathological examination of  liver samples and also sup-
ported by the work of  Zhao et al (2005). Stem cells were given at 
a dose of  107 cells per rat to establish humanized rat xenograft 
model. On day 0, rats were divided into the following groups:
 
1. Control group: 10 rats received 0.2 mL/100 g body weight 
of  castor oil twice a week for 6 weeks.
2. CCl4 group: 10 rats received 0.2 mL/100 g body weight of  
CCl4 by the schedule mentioned above. Liver fibrosis was de-
termined by histopathological examination.
3. CCl4/MSCs group: involved 10 rats that received 0.2 
ml/100 g body weight of  CCl4 by the schedule mentioned 
above. The rats were infused with a dose of  107 undifferenti-
ated cells per rat intraperitoneally (IP) according to Zhao et 
al [14]. 
4. CCl4/CD34+ group: involved 10 rats that received 0.2 
ml/100 g body weight of  CCl4 by the schedule mentioned 
above. The rats were infused with a dose of  107 undiffer-
entiated cells per rat intraperitoneally (IP) according to Di 
Campli et al [15].
 
Analysis of  liver histopathology
 
Liver samples were collected into PBS and fixed overnight in 40 
g/L paraformaldehyde in PBS at 4°C. Serial 5-μm sections of  the 
right lobes of  the livers were stained with hematoxylin and eosin 
(HE) and were examined histopathologically.
 
Quantitave RT-PCR analysis for collagen I and MMP-2 
 
Total RNA was extracted from liver tissue homogenate using 
RNeasy purification reagent (Qiagen, Valencia, CA). cDNA was 
generated from 5 μg of  total RNA extracted with 1 μl (20 pmol) 
antisense primer and 0.8 μl superscript AMV reverse transcriptase 
for 60 min at 37°C. The relative abundance of  mRNA species was 
assessed using the SYBR® Green method on an ABI prism 7700 
sequence detector system (Applied Biosystems, Foster City, CA) 
[16]. PCR primers were designed according to Morimoto et al. 
2011 [17]. All primer sets had a calculated annealing temperature 
of  60°. Quantitative RT-PCR was performed in duplicate in a 25-
μl reaction volume consisting of  2X SYBR Green PCR Master 
Mix (Applied Biosystems), 900 nM of  each primer and 2–3 μl 
of  cDNA. Amplification conditions were 2 min at 50°, 10 min at 
95°and 40 cycles of  denaturation for 15 s and annealing/exten-
sion at 60° for 10 min. Data from real-time assays were calculated 
using the v1•7 Sequence Detection Software from PE Biosystems 
(Foster City, CA). Sequence of  the murine primers used for real-
time PCR:
Gene Primer Sequence
Collagen-1 Forward 5’- CAA GAA TGG CGA CCG TGG TGA-3' 
Reverse 5’- GGT GTG ACT CGT GCA GCC ATC-3'
MMP-2 Forward 5’- GAG ATC TGC AAA CAG GAC AT-3'      
Reverse 5’- GGT TCT CCA GCT TCA GGT AA-3'
Statistical analysis: Data are expressed as Mean ± SD. Signifi-
cant differences were determined using ANOVA and post hoc 
tests for multiple comparisons using SPSS 15.0 computer Soft-
ware. P values of  < 0.05 were considered significant.
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Histopathological examination of  liver tissue showed that two 
types of  stem cells have a significant antifibrotic effect as evi-
denced by the decrease in liver extracellular matrix (ECM) com-
pared to the CCl4 group (Fig. 1).
The collagen I gene expression
There was a significant difference (p<0.05) in gene expres-
sion of  all groups compared to normal group. CCl4, MSCs, 
and CD34+ groups showed a significant increase (1.02±0.26, 
0.50±0.21 & 0.51±0.23) respectively, compared to the normal 
group (0.12±0.03). Meanwhile, stem cell received groups showed 
a significant decrease in gene expression compared to the CCl4 
group. Also, there was no significant difference between stem cell 
A B
C
Figure 1. Photomicrographs of  liver tissue stained with H&E showing normal hepatic lobules from control rats in a (100x), 
marked increase in ECM with dense bundles of  collagen surrounding hepatic lobules forming large fibrous septa from 

































Figure 2. A histogram showing the expression of  collagen 1 in all groups. 
*: statistically significant compared to corresponding value in group I (P<0.05)
#: statistically significant compared to corresponding value in group II (P<0.05)
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received groups (Fig.2).
The MMP-2 gene expression
MMP-2 mRNA was significantly increased (p<0.05) in fibrotic 
liver group and CD34+ treated group (0.91±0.05 & 0.46±0.18) 
compared to normal group (0.24±0.06). On the other hand, 
MMP-2 gene expression was significantly decreased (p<0.05) 
in the MSCs group (0.40±0.18) and CD34+ group compared to 
CCl4 group, and there was no significant difference between stem 
cell received groups (Fig.3).
Correlation between type 1 collagen and MMP-2 gene ex-
pression
 
Using pearson correlation, the results showed that a strong positive 
correlation (p<0.05) in the expression of  both genes. When the 
level of  collagen 1 expression increased, the level of  MMP-2 ex-
pression also increased (R. linear) as illustrated in figure (4). 
Discusion
The liver is responsible for many critical functions in the body and 
loss of  those functions may leads to damage of  the body. Hepatic 
fibrosis (HF) represents a scarring response to either acute or 
chronic cellular injury. The scar is typically composed of  fibrillar 
collagen type I and III, proteoglycans, fibronectin and hyaluronic 
acid [18]. As a result, alteration in the physiological architecture 
of  the liver occurs, particularly in the space of  Disse, where the 
low electron-dense ECM is replaced by one rich in fibrillar col-
lagens and fibronectin. This leads to loss of  endothelial cell fen-
estrations, impaired exchange of  solutes among neighboring cells, 
































Figure 3. A histogram showing the expression of  MMP-2 in all groups.
*: statistically significant compared to corresponding value in group I (P<0.05)
#: statistically significant compared to corresponding value in group II (P<0.05
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damage [19]. Carbon tetrachloride-induced fibrosis and cirrhosis 
is one of  the oldest and probably the most widely used toxin-
based experimental model for the induction of  fibrosis. It has 
the advantages that it has been clearly characterized and in many 
respects mirrors the pattern of  disease seen in human fibrosis and 
cirrhosis associated with toxic damage [20,21]. In this study, when 
rats were treated with CCl4 twice weekly for 6 weeks, the liver 
exhibited a marked increase in extracellular matrix (ECM) con-
tent and displayed bundles of  collagen surrounding the lobules 
leading to large fibrous septa. All of  these are characteristics of  
advanced fibrosis. Meanwhile, histopathologic examination of  liv-
ers showed decreased fibrosis after administration of  MSCs and 
CD34+ stem cells, this in agreement with Abdel Aziz et al. [22] 
and Di Campli et al. [15]. Also the molecular results in this study, 
detected a significant increase in gene expression of  collagen type 
I and MMP-2mRNA in rats given CCl4 than rats with only castor 
oil, and this with agreement with the study of  Abdel Aziz et al. 
[22] and Kollet et al. [23]. Liver fibrosis refers to the accumula-
tion of  extracellular matrix (ECM) proteins, which occurs in most 
types of  chronic diseases. Of  these proteins, collagen, which is 
the body’s self-repairing protein induced by inflammation, most 
commonly accumulates [24]. At the early stage of  liver fibrosis, 
collagen type IV increases first and then gradually decreases, while 
the collagen type III increases and expresses predominantly. In 
the developing and advanced stages, the collagen type I gradu-
ally increased, and collagen of  both type I and II significantly in-
creased, especially the type I [25,26.27]. In the progression of  liver 
fibrosis, MMP-2 is also involved in the degradation of  fibrotic 
matrix [28]. An interesting recent observation is that HSCs-medi-
ated activation of  MMP-2 is significantly induced in the presence 
of  collagen type I (the principal matrix protein found in fibrotic 
liver) [29]. This could contribute to further degradation of  the 
normal liver matrix, leading to increased activation of  HSCs and 
increased synthesis of  type I collagen. This positive feedback loop 
would theoretically promote progression of  liver fibrosis [30]. 
Stem cell-based cytotherapy has shown promising benefit on ani-
mal models and some clinical patients [31]. The result of  the pre-
sent work showed strong red auto fluorescence after transplanta-
tion in rats, confirming that these cells were actually insinuating 
themselves into the liver tissue as detected by fluorescent micro-
scope. Molecular mechanisms underlying stem cells mobilization 
and homing into the injured liver are still poorly understood [32]. 
Naturally, the migration, differentiation and growth are mediated 
by the tissue, degree of  injury and SCs involved. Damaged tissue 
releases factors that induce SCs homing. In our study, quantitative 
RT-PCR analysis detected a significant reduction in the indicators 
of  liver fibrosis such as collagen I and MMP-2 gene expression 
showed decrease in mRNA level after MSCs administration and 
this in agreement with Abdel Aziz et al. [33]. In an attempt to 
reveal the underlying mechanism, Prosser et al. demonstrated that 
(a) MSCs were able to produce hepatocyte growth factor (HGF), 
which in turn could promote the MSCs to undergo the process of  
trans-differentiation into parenchymal hepatocyte [34]. (b) MSCs 
prevent the liver from undergoing fibrogenesis via secreting a va-
riety of  cytokines, such as HGF, interleukin (IL)-6 and -10 and 
so on. These cellular factors may inhibit hepatic fibrosis through 
multiple mechanisms. (c) MSCs may dissolve fibrosis directly. 
There was evidence suggesting that MSCs were able to produce 
the matrix metalloproteinase (MMPs), an enzyme capable of  de-
grading the extracellular matrix, which alleviates hepatic cirrhosis 
directly [35]. On the other hand, umbilical cord blood contains 
a higher amount of  hematopoietic stem cells compared with 
bone marrow. The immaturity of  umbilical cord blood stem cells 
(UCBSCs) affords them numerous advantages over adult bone 
marrow-derived stem cells (BMSCs) in cell transplantation[36]. 
Controversy has recently arisen as to whether HSCs contribute to 
the hepatocyte lineage in liver injury via transdifferentiation alone 
or by adopting the phenotype of  hepatocytes after spontaneous 
cell fusion [37]. Recent reports in favor of  the fusion hypoth-
esis have demonstrated that adult cells can adopt the phenotype 
of  other cell lines by fusing with embryonal stem cells [38,39] 
as well as BM-derived hepatocytes generated by in vivo cell fu-
sion [40]. In support of  transdifferentiation, several groups have 
demonstrated that HSCs can differentiate into hepatocytes [8,41] 
and pancreatic endocrine cells [42] without any evidence of  cell 
fusion. Whatever the mechanism of  hepatic regeneration is, the 
trafficking of  HSCs to the liver may play an important compo-
nent of  the reparative process in liver injury [43]. Finally, where 
there are controversial about the mechanism by which MSCs re-
pair liver fibrosis, our study tend to that BM-derived stem cells 
exert a paracrine proliferative effect on endogenous hepatocytes, 
as evidenced by studies of  experimental animals and humans. The 
self-renewal potential of  endogenous hepatocytes in cirrhotic liv-
er is compromised, and they might acquire replicative senescence 
after many rounds of  injury and repair [44,45].
 
Conclusion
Transplantation of  BM-MSCs and UCB-HSCs ameliorate CCl4-
induced liver fibrosis in rats mediated by the improvement of  
fibrogenesis by decreasing expression of  collagen type I and sub-
sequently MMP-2 gene expression. Furthermore, studies with 
longer follow up are required to confirm the safety of  this therapy. 
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